In addition to the GMP license, Canexis Pharma AG has also acquired the narcotics (BTM) operating license to handle controlled substances. This allows the purchase, processing and refinement, as well as the trade of cannabis active ingredients with a THC percentage >1%. This allows controlled pilot trials to be supported in Switzerland, but also allows doctors to prescribe medical cannabis in the form of a magistral prescription.
Currently, custom-made prescription drugs dominate the medical cannabis market. We plan to enrich this market with a range of finished medicinal products based on pure active ingredients extracted directly from the plant. Canexis' production facility can process up to 1000 kg of cannabis per day, resulting in 100 kg of pure active ingredients per day. This means Canexis can meet the daily needs of one to four million patients.
Canexis Pharma AG has all the official permits and technical capabilities to meet the increasing demand for medical cannabis of the highest quality and for individual wishes.
More about our certificates and approvals here.